Study of Envolizumab and Radiotherapy Before Surgery for Locally Advanced Thymic Cancer

What this Trial Is About

Researchers are evaluating the combination of Envolizumab and radiotherapy as a neoadjuvant treatment for patients with locally advanced thymic carcinoma. This single-arm, phase II clinical trial aims to confirm the feasibility, safety, and effectiveness of this combination in improving surgical outcomes and to develop unified criteria for assessing pathological remission after neoadjuvant therapy in thymic cancer. The treatment includes delivering 20-40 Gy of radiotherapy over 10-20 sessions. Within one week after starting radiotherapy, patients receive subcutaneous injections of Envolizumab 300 mg every three weeks for 2 to 4 cycles as maintenance therapy. Surgery is planned after treatment evaluation by the attending physician. Participants will be closely monitored through various assessments including pathological examination of surgical specimens to evaluate remission status. Key outcomes measured include objective response rate, disease control rate, radical resection rate, pathological remission rate, and long-term disease-free and overall survival over five years. Safety and treatment adherence will also be tracked throughout the study period.

Neoadjuvant Treatment For Locally Advanced Thymic Cancer